Table 3 Outcomes
Avacopan (n = 21) | |
|---|---|
Primary outcome | |
Clinical remission at 6 months | 20 (95.2%) |
Clinical remission at 12 months | 19 (90.5%) |
Secondary outcomes | |
Clinical relapse | 3 (14.3%) |
Change in eGFR, mL/min/1.73 m2 (baseline to 6 months) | +7 (3–12) |
Change in eGFR, mL/min/1.73 m2 (baseline to 6 months) | +15 (7–21) |
ESKD | 0 |
Infection requiring hospitalization | 2 (9.5%) |
Death | 0 |
BVAS at 6 months | 0 |
BVAS at 12 months | 0 |
Observation period, months | 14 (13–18) |